Guilherme Nader Marta

Guilherme Nader Marta: Phase 3 ALEXANDRA/IMpassion030 trial found no benefit of adjuvant atezolizumab and chemo for TNBC

Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent paper by Michail Ignatiadis et al. published in JAMA:

“Phase 3 ALEXANDRA/IMpassion030 trial (n=2199) published in JAMA found no benefit of adjuvant atezolizumab and chemo vs chemo alone for high-risk early-stage TNBC (IDFS HR 1.11, 95% CI 0.87-1.42).

Higher grade 3-4 toxicity (54% vs 44%).”

“Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial”

Authors: Michail Ignatiadis et al.

Guilherme Nader Marta: Phase 3 ALEXANDRA/IMpassion030 trial found no benefit of adjuvant atezolizumab and chemo for TNBC

More posts featuring Guilherme Nader Marta.

atezolizumab cancer Guilherme Nader Marta Michail ignatiadis OncoDaily Oncology TNBC